following a full submission:
sofosbuvir-velpatasvir (Epclusa®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.
SMC restriction: in patients with
• genotype 2, 5 or 6 chronic HCV infection
• decompensated cirrhosis, irrespective of chronic HCV genotype
Sofosbuvir-velpatasvir was associated with high rates of sustained virologic suppression in adults with genotype 1, 2, 4, 5 and 6 chronic HCV infection, including those with decompensated cirrhosis. Sofosbuvir-velpatasvir was associated with significantly superior sustained virologic suppression compared with sofosbuvir plus ribavirin in adults with genotype 2 chronic HCV infection.
SMC has issued separate advice accepting the use of sofosbuvir-velpatasvir for the treatment of patients with genotype 3 chronic HCV infection.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sofosbuvir-velpatasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice299KB (PDF)
Medicine details
- Medicine name:
- sofosbuvir/velpatasvir (Epclusa)
- SMC ID:
- 1271/17
- Indication:
- Treatment of chronic hepatitis C virus (HCV) infection in adults
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 October 2017